Russell Smith

Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK

Surface Therapeutics Ltd. develops novel drugs & diagnostics for asthma and epithelial diseases. It also develops new pharmaceutical products for the treatment of inflammatory epithelial diseases with a focus on the skin and lungs. The company was founded in 2004 and is headquartered in Abingdon, LO.

Business Boffins Ltd. provided education management services. The company was headquartered in Chinnor, the United Kingdom.

Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK.

Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom.